Metabolon, the RTP-based life science company focusing on the science of metabolomics, is expanding its management team with a new chief medical officer. The firm also promotes an exec to CFO.
Dr. David Memel has accepted the CMO post as Metabolon beefs up its management following two recent fundraisers that netter the firm some $30 million.
“This is a new position,” a Metabolon spokesperson told WRAL TechWire.
“Our goal is to expand our precision medicine initiatives. We are at a stage where we need senior-level medical leadership to deliver those products to the clinic.”
Metabolon, which launched in 2000, defines metabolomics as the study of small molecules called metabolites and is a powerful phenotyping technology for precision medicine. It measures changes in metabolite levels and maps them to the appropriate biochemical pathways to give clinicians a better understanding of health and the influences of genes, microbiome, diet, lifestyle and drug treatment.
Memel most recently was the Managing Director of Klaipeda Health, a healthcare and life sciences advisory company.
“We’re pleased to have David join our leadership team,” said John Ryals, Metabolon’s CEO. “He has made significant contributions to the development and commercialization of many pharmaceutical and diagnostic products; led development and implementation of a variety of healthcare and life sciences technologies, analytics and evidence-based services and solutions; and built and led high-performing teams to deliver new capabilities and value. I am confident that his broad experience will help us build the clinical capabilities that are critical to achieving Metabolon’s Precision Medicine vision.”
Promoted to CFO was Frank Fee III who had been Senior Vice President, Finance. He’s been with Metabolon since 2011 and was deeply involved in the 2016 fundraisers.
“Frank has demonstrated his finance and accounting expertise and a deep understanding of our industry and company,” Ryals said. “As Chief Financial Officer, I know that he will continue to be a strong financial and strategic partner as we continue to grow our business.”
